Thus, the AURKA inhibitor (alisertib) and the EZH2 inhibitor (gambogenic acid) may offer a potential therapeutic opportunity for HCC patients with TP53 mutations, as TP53 is the most frequently mutated tumor suppressor gene in HCC. The gene discussed is TP53; the disease is hepatocellular carcinoma.